(C) 2008 Elsevier Inc. All rights reserved.”
“The stable polyurethane-epoxy composite emulsion with the epoxy-amine oligomer (DEA-EP) and the epoxy resin oligomer

has been prepared by step-growth polymerization and controlled crosslinking technique. The emulsion forming transparent films can be cured at room temperature with trimethylolpropane tris (I-ethyleneimine) properties (TMPTA-AZ). The DEA-EP structure and its reaction with urethane prepolymers were proved by Fourier transform infrared spectra (FTIR). The studies on particle size, the particle size distribution, viscosity, and the films’ transmittance (Tr) indicated that both trimethylol propane (TMP) and DEA-EP contributed to improving the resin blends’ compatibility and reducing the viscosity. The epoxy Selleck GSK2126458 resin content can increase up to 20.0 wt % (based on the total content of the polyurethane and epoxy resin) and the emulsion was still stable. The data from the tensile test experiments GW786034 price showed that with the epoxy content increasing, the tensile strength (sigma(b)) and Young’s modulus were proportionately raised, but the elongation at break (epsilon(b)) decreased. Tensile tests also revealed that introducing TMPTA-AZ as an outside-crosslinker

can increase the tensile strength. By adding 0.3 wt % of TMPTA-AZ, the epsilon(b) reduced from 429% to 371% and the sigma(b) increased from 4.4 to 13.73 MPa; by adding 1.8 wt % of TMPTA-AZ, epsilon(b) of the film was 67% of

epsilon(b) of PLX4032 the film with 0.3 wt % of TMPTA-AZ, but its sigma(b) was 24.77 MPa and 180% of sigma(b) of the film with 0.3 wt % of TMPTA-AZ. The cured films possessed excellent water and toluene resistance: water uptake (48 h, 3.1%; degree of curing: 70%), toluene uptake (210 h, 8%. degree of curing: 70%). Better properties of the composite emulsion will confer it as a potential application in low volatile industrial coatings. (C) 2009 Wiley Periodicals, Inc. J Appl Polym Sci 115: 451-459, 2010″
“Background The successful treatment of psoriasis depends not only on the efficacy of the medication but also on patientsi acceptance and adherence to the prescribed regimen. Patients and Methods In this non-interventional, prospective trial 579 patients with psoriasis were treated once daily with the fixed combination of calcipotriol 50 g/g plus betamethasone 0.5 mg/g (Daivobet (R) Gel) for 4 weeks. Comparing the new medication to their previous treatment, patients assessed their quality of life by means of the Dermatology Life Quality Index (DLQI), reported their therapy- associated burden in daily life by the Psoriasis Disability Index (PDI) and assessed how easy the new medication was to employ. Disease severity was rated at the start and end of the study by physicians and patients using a Global Assessment (PGA from 05 points) and the Body Surface Area (BSA) assessed by the physicians. Results Quality of life improved from 8.7 to 3.